Fri, Aug 1, 2014, 9:53 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Alnylam Pharmaceuticals, Inc. Message Board

  • robert.vince robert.vince Oct 9, 2012 8:52 AM Flag

    Alnylam Announces Tuschl II Key Patent Claims Upheld in Invalidation Trial in Japan

    Alnylam Pharmaceuticals, Inc. (ALNY), a leading RNAi therapeutics company, announced today that the Japanese Patent Office upheld key claims in the Tuschl II patent (JP4095895) in an invalidation trial held in Japan. The invalidation request was made by Bio Think-Tank, a Japanese company.

    “We are extremely pleased with the outcome of the invalidation trial which resulted in key claims from the Tuschl II ’895 patent being upheld in Japan. This affirms our belief in the validity of these claims and the groundbreaking nature of the Tuschl II invention forming the basis of this critical patent family,” said Laurence Reid, Ph.D., Senior Vice President, Chief Business Officer at Alnylam. “Tuschl II remains a valuable patent in our overall broad estate of patents important for the development and commercialization of RNAi therapeutics, and a patent family to which we are the exclusive licensee. We look forward to the continued advancement of the Tuschl II patent family worldwide in conjunction with many other Alnylam-held patents and pending patent applications.”

    “We are gratified that the Japanese Patent Office has upheld these claims from Tuschl II,” said Dr. Joern Erselius, Managing Director, Max Planck Innovation GmbH. “The successful examination of the Tuschl II patent series highlights that this invention is seminal for RNAi, demonstrating the importance of the work performed by Professor Tuschl and other co-inventors at the Max Planck Institute.”

    The Tuschl II patent series provides broad exclusivity for small interfering RNA (siRNA), the molecules that mediate RNAi, in the world’s top pharmaceutical markets, which include the U.S. (US 7,056,704 and US 7,078,196), the European Union (EP 1407044), China (CN100523215), and Japan (JP4095895 and JP4494392). Specifically, the Japanese Tuschl II ’895 patent broadly covers compositions, methods, and uses of siRNA that are important for the development and commercialization of RNAi therapeutics. The Tuschl II patent family is exclusively licensed to Alnylam for RNAi therapeutics on a worldwide basis through an agreement with Max Planck Innovation GmbH, the licensing agent for the Max Planck Society.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That's unexpected bad news

      1) the company didn't bother to tell us
      2) which claims are lost?

      • 1 Reply to rnai_inv
      • Based on this statement, it looks like this was a positive announcement:

        “We are extremely pleased with the outcome of the invalidation trial which resulted in key claims from the Tuschl II ’895 patent being upheld in Japan. This affirms our belief in the validity of these claims and the groundbreaking nature of the Tuschl II invention forming the basis of this critical patent family,” said Laurence Reid, Ph.D., Senior Vice President, Chief Business Officer at Alnylam. “Tuschl II remains a valuable patent in our overall broad estate of patents important for the development and commercialization of RNAi therapeutics, and a patent family to which we are the exclusive licensee. We look forward to the continued advancement of the Tuschl II patent family worldwide in conjunction with many other Alnylam-held patents and pending patent applications.”

 
ALNY
53.71-0.41(-0.75%)Aug 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.